Trials that use: Odds ratio
New to this method? Read the tutorial →
5,976 results
- SWIFTIndependent statistical analysis of SOLITAIRE™ FR With the Intention For Thrombectomy (SWIFT) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01054560).
- SWIPEIndependent statistical analysis of Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SWITCHIndependent statistical analysis of Sleep Without Insomnia or The Use of Chronic Hypnotics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03687086).
- SWITCH 2Independent statistical analysis of A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes: primary endpoint results, effect estimate…
- Sym004 in Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Sym004 in Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01117428).
- SYMPATICOIndependent statistical analysis of Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- SYMPHONYextIndependent statistical analysis of Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Symplicity AFIndependent statistical analysis of Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Symptoms-StepsIndependent statistical analysis of In Person and mHealth Coping Skills Training for Symptom Management and Steps in Stem Cell Transplant Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Synagis RussiaIndependent statistical analysis of A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and…
- T-cell Depleted Alternative Donor Transplantation: Complete Statistical AnalysisIndependent statistical analysis of T-cell Depleted Alternative Donor Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00968864).
- T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery: Complete Statistical AnalysisIndependent statistical analysis of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery: primary endpoint results, effect estimate with confidence interval, sample-size…
- T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00939653).
- TACACIndependent statistical analysis of Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00206518).
- Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX: Complete Statistical AnalysisIndependent statistical analysis of Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer: primary endpoint results,…
- TACTIC AFIndependent statistical analysis of Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- TactiSenseIndependent statistical analysis of TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03354663).
- TAILOR-PCIIndependent statistical analysis of Tailored Antiplatelet Therapy Following PCI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01742117).
- Tailored Approaches to Improve Medication Adherence: Complete Statistical AnalysisIndependent statistical analysis of Tailored Approaches to Improve Medication Adherence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01643473).
- Tailored-AFIndependent statistical analysis of Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04702451).
- Tailoring Shared Decision Making for Lung Cancer Screening in Persons Living With HIV: Complete Statistical AnalysisIndependent statistical analysis of Tailoring Shared Decision Making for Lung Cancer Screening in Persons Living With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Tailoring Treatment Targets for Early Autism Intervention in Africa: Complete Statistical AnalysisIndependent statistical analysis of Tailoring Treatment Targets for Early Autism Intervention in Africa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04068688).
- TAK-114 Single- and Multiple-Dose Phase 1 Study: Complete Statistical AnalysisIndependent statistical analysis of TAK-114 Single- and Multiple-Dose Phase 1 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02286518).
- TALAPRO-2Independent statistical analysis of Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03395197).
- Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval,…
- Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML): Complete Statistical AnalysisIndependent statistical analysis of Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- TANDEMIndependent statistical analysis of Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis: primary endpoint results, effect estimate with…
- Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment: Complete Statistical AnalysisIndependent statistical analysis of Tandem Auto Transplantation in Myeloma Patients With
- TAPIndependent statistical analysis of Transversus Abdominis Plane (TAP) Block Using Liposomal Bupivacaine in Metabolic and Bariatric Surgery Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- TAP HYSIndependent statistical analysis of Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01074229).
- TAPASIndependent statistical analysis of TissuePAtchDS--P ™ PArotidectomy Trial.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04116762).
- TAPERIndependent statistical analysis of Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal: primary endpoint results, effect estimate with confidence interval,…
- TARGETIndependent statistical analysis of Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- TARGETIndependent statistical analysis of Role of On-site CT-derived FFR in the Management of Suspect CAD Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: Complete Statistical AnalysisIndependent statistical analysis of Targeting Cellular Senescence With Senolytics to Improve Skeletal Health in Older Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Targeting IL-17A for Treatment-Resistant Depression: Complete Statistical AnalysisIndependent statistical analysis of Targeting IL-17A for Treatment-Resistant Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04979910).
- TARMICIndependent statistical analysis of Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- TAS3351Independent statistical analysis of A Study of TAS3351 in NSCLC Patients With EGFRmt: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05765734).
- TASCIndependent statistical analysis of Aortoiliac Stenosis in Kidney Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06020534).
- TASCIndependent statistical analysis of Transatlantic Active Surveillance on Cardiovascular Safety of NuvaRing (TASC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00524771).
- TASTERIndependent statistical analysis of Ticagrelor Administered as Standard Tablet or Orodispersible Formulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03822377).
- TAXYNERGYIndependent statistical analysis of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC): primary endpoint results, effect estimate with…
- TBKT_HEPIndependent statistical analysis of Thera-Band® HEP for LBP Secondary Prevention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02355275).
- TCM-700CIndependent statistical analysis of The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- TD-0903 for ALI Associated With COVID-19: Complete Statistical AnalysisIndependent statistical analysis of TD-0903 for ALI Associated With COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04402866).
- Tdap Vaccine Safety for Plasma Donors: Complete Statistical AnalysisIndependent statistical analysis of Tdap Vaccine Safety for Plasma Donors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04142983).